Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 10/3/2025

FDA-Recommended Primary Endpoint for HIV Switch Trials

Evidence Supporting 48-Week Endpoint

  • The FDA recommends checking viral load 1 month after switching to ensure initial maintenance of suppression, but this does not constitute the primary efficacy endpoint, according to guidelines from the American Medical Association, as reported in JAMA 1, 2

Measuring Suppression vs. Virologic Failure

  • Guidelines recommend checking viral load at specific timepoints, such as 1 month post-switch, for safety monitoring, but the primary efficacy endpoint remains at 48 weeks, as stated in JAMA 1, 2